May 17, 2018 / 12:23 PM / 9 days ago

BRIEF-Trial shows Pfizer's Lyrica reduces seizures in children with epilepsy

May 17 (Reuters) - Pfizer Inc:

* LYRICA® (PREGABALIN) ORAL SOLUTION CV PHASE 3 TRIAL IN PEDIATRIC EPILEPSY MEETS PRIMARY ENDPOINT

* PFIZER - POSITIVE TOP-LINE RESULTS OF PHASE 3 STUDY EXAMINING USE OF LYRICA ORAL SOLUTION CV AS ADJUNCTIVE THERAPY

* PFIZER - RESULTS SHOWED ADJUNCTIVE TREATMENT WITH LYRICA 14 MG/KG/DAY RESULTED IN STATISTICALLY SIGNIFICANT REDUCTION IN SEIZURE FREQUENCY VERSUS PLACEBO

* PFIZER INC - TREATMENT WITH LYRICA AT LOWER DOSE DID NOT RESULT IN STATISTICALLY SIGNIFICANT REDUCTION IN SEIZURE FREQUENCY VERSUS PLACEBO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below